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Simple Summary: A review of over six decades of cancer chemotherapies, including recent im-
munotherapy, reveals partial success in the battle against cancer. One of the main reasons for this
slow progress is the failure, by mainstream anticancer treatments, to distinguish between cancer cells
and normal cells. For this reason, the aim of our study was to assess if sonodynamic therapy (SDT), a
new anticancer approach, can affect cancer cells only, avoiding any harmful effects on normal cells.
SDT aims to cure malignant tumors by using a chemical compound (sonosensitizer) triggered by
ultrasound exposure. For this purpose, the effects on cancer cells and normal cells, namely HT-29
cells and HDF 106-05 cells, subjected to sonodynamic treatment were investigated. Our results show
that, according to different plasma membrane properties of cancer cells and normal cells, a different
sonodynamic effect occurs, reaching a remarkable cytotoxic effect on cancer cells only.
Abstract: Sonodynamic Therapy (SDT) is a new anticancer strategy based on ultrasound (US)
technique and is derived from photodynamic therapy (PDT); SDT is still, however, far from clinical
application. In order to move this therapy forward from bench to bedside, investigations have been
focused on treatment selectivity between cancer cells and normal cells. As a result, the effects of
the porphyrin activation by SDT on cancer (HT-29) and normal (HDF 106-05) cells were studied in
a co-culture evaluating cell cytotoxicity, reactive oxygen species (ROS) production, mitochondrial
function and plasma membrane fluidity according to the bilayer sonophore (BLS) theory. While PDT
induced similar effects on both HT-29 and HDF 106-05 cells in co-culture, SDT elicited significant
cytotoxicity, ROS production and mitochondrial impairment on HT-29 cells only, whereas HDF
106-05 cells were unaffected. Notably, HT-29 and HDF 106-05 showed different cell membrane
fluidity during US exposure. In conclusion, our data demonstrate a marked difference between
cancer cells and normal cells in co-culture in term of responsiveness to SDT, suggesting that this
different behavior can be ascribed to diversity in plasma membrane properties, such as membrane
fluidity, according to the BLS theory.
Keywords: ultrasound; sonodynamic therapy; porphyrin; cancer cells; membrane fluidity
1. Introduction
Cancer is a major public health problem worldwide and therefore, continuous scientific
efforts in this field are clearly needed [1]. Therefore, in recent decades, thanks mainly to
Cancers 2021, 13, 3852. https://doi.org/10.3390/cancers13153852 https://www.mdpi.com/journal/cancers
Cancers 2021, 13, 3852 2 of 18
increasing knowledge on cancer molecular biology and growing interest in applying bio-
and nano-technology techniques against this pathology, cancer therapeutic strategies have
notably changed [2,3]. However, despite these advancements, the overall cancer death
rate still remains high as the critical issue of targeting cancer cells with high selectivity has
not been reached for most cancers [4]. For this reason, novel and challenging therapeutic
approaches must be explored to improve selectivity for cancer cells over normal cells to
avoid systemic toxicity and to overcome drug resistance [5].
In order to investigate new therapeutic anticancer approaches able to improve can-
cer selectivity, we have investigated sonodynamic therapy (SDT), a therapeutic strategy
derived from photodynamic therapy (PDT), based on the synergistic effect triggered by
combining a suitable chemical compound (sonosensitizer) and low-intensity ultrasound
(US), which is used to kill cancer cells and microbial cells [6,7]. The anticancer effectiveness
of SDT has been demonstrated in in vitro and in vivo animal models [8–11]. Despite the
promising results of this approach, however, only a few clinical reports have described
the use of SDT [6]. In our opinion, for SDT to be quickly turned into the clinical setting, a
deeper understanding of its mechanism of action and its potentiality is needed. Therefore,
the aim of our work was to shed new light on the SDT mechanism of action and to under-
stand if selectivity towards cancer could be one of the main features of this approach. To
this end, in our previous investigations, different outcomes of cancer cells and normal cells
to SDT were reported, supporting the finding that cancer cells and normal cells behave
differently in response to SDT [12]. Indeed, it has been suggested that cell responsiveness to
US is different between cancer cells and normal cells as the resistance of these cell types to
physical stress is not the same [13]. Moreover, recently, Geltmeier and colleagues reported
that a tension/compression force of US can provoke damage preferentially on cancer cells,
compared to normal cells [14].
To achieve our goals, SDT experiments were carried out in cancer and normal cell lines,
namely the human colon cancer HT-29 cell line and the dermal fibroblast HDF 106-05 cell line,
in co-culture to provide a more representative in vivo-like tissue model [15] and to avoid any
misinterpretation of the results when the same experiments are performed separately.
Since the generation of reactive oxygen species (ROS) is considered a pivotal step
in SDT anticancer activity, we performed our STD experiments with a palladium (II)
porphyrin complex (Pd-P) as a sonosensitizer because, under US exposure, it resulted in
being the most efficient sonosensitizer, compared to other metal–porphyrin complexes
such as iron (III) and zinc (II) porphyrin complexes, in generating singlet oxygen (1O2)
and hydroxyl radicals (•OH), and in US-mediated cancer cell killing [12]. Therefore, the
selective cytotoxicity of SDT towards cancer HT-29 cells co-cultured with normal HDF
106-05 cells was evaluated in terms of cell death and ROS generation. In addition, we tried
to elucidate the SDT mechanism of action by investigating the possible process responsible
for selective responsiveness of cancer cells to SDT treatment. Firstly, we hypothesized
that the intracellular activation of the sonosensitizer was probably due to a US-mediated
energy transfer in the form of intramembrane cavitation across the cytoplasmic membrane
according to the bilayer sonophore (BLS) theory, suggesting that the cell type-dependent
responsiveness to SDT could rely on specific plasma membrane features. Secondly, we
hypothesized that mitochondria were involved as the main intracellular target of SDT
in the cell type-dependent SDT response [16,17]. For this reason, the plasma membrane
diversity between cancer cells and normal cells was investigated in terms of SDT impact
on plasma membrane fluidity, while the mitochondrial membrane potential was studied to
confirm the pivotal role of these intracellular organelles in the efficacy of SDT.
2. Materials and Methods
2.1. Preparation of Porphyrin-Metal Complex Solution
5,10,15,20-tetrakis(N-methylpyridinium-4-yl) porphyrinato palladium (II) tetrachlo-
ride (Pd-P) was synthesized according to the method described by Giuntini et al. [12]. In
order to obtain a 2 mM solution, 9.2 mg of Pd-P powder (MW 925.05 g/mol) was reconsti-
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tuted in 5 mL cell medium without serum that was then filtered with sterile syringe filter
membrane 0.2 µm (Enrico Bruno S.r.l., Torino, Italy) and stored in 1 mL aliquots at −20 ◦C
away from the light.
2.2. Cell Culture
The human Caucasian colon adenocarcinoma cell line, HT-29 (Interlab Cell Line
Collection, Genova, Italy), was cultured as a monolayer in RPMI-1640 growth medium
(Sigma-Aldrich, Milano, Italy). The normal adult human primary dermal fibroblast cell
line, HDF 106-05 (ECACC, Salisbury, UK), was cultured as a monolayer in DMEM growth
medium (Sigma-Aldrich). Both cell culture media were supplemented with 10% decomple-
mented fetal bovine serum (FBS) (Lonza, Verviers, Belgium), 2 mM-glutamine, 100 UI/mL
penicillin and 100 µg/mL streptomycin antibiotic (Sigma-Aldrich). Both cell lines were
maintained in a dark incubator (Thermo Fisher Scientific, Waltham, MA, USA) in a humidi-
fied atmosphere containing 5% CO2 at 37 ◦C.
HT-29 and HDF 106-05 Cell Co-Culture
For the co-culture sonodynamic and photodynamic experiments, equal amounts of
HT-29 and HDF 106-05 cells were used (1:1), with a final concentration of 5 × 105 cells. In
particular, HT-29 and HDF 106-05 cells were maintained in co-culture with an equal mix of
the respective cell culture medium.
2.3. Intracellular Porphyrin Fluorescence Quantification
According to our previous work [12], the non-cytotoxic Pd-P concentration required
to perform sonodynamic and photodynamic treatment on HT-29 and HDF 106-05 cells was
500 µM for P-Pd. In order to ascertain the correct time of sonosensitizer incubation before
performing sonodynamic and photodynamic treatment, semiquantitative intracellular
uptake of Pd-P in HT-29 and HDF 106-05 cells was investigated using the fluorescence
plate reader EnSight (PerkinElmer, Waltham, MA, USA). Briefly, 5 × 103 HT-29 and HDF
106-05 cells were cultured in total black 96-well plates and, 24 h after seeding, cells were
incubated for 1, 6, 12 and 24 h with Pd-P at 500 µM, respectively. Prior to analysis, culture
media was removed, cells were washed with PBS, and nuclei were stained with 4′, 6-
diamidino-2-phenylindole (DAPI) 2 µL/mL for 10 min, then fixed with paraformaldehyde
(PAF) 4% solution (Sigma-Aldrich) for 10 min at room temperature. Each well was then
supplemented with 200 µL PBS for plate reading according to the plate normalization
procedure for top reading setting.
DAPI is a blue, fluorescent, nucleic acid stain that preferentially stains double-stranded
DNA. The detected fluorescence is directly proportional to the amount of DNA present
in the cell, and as DAPI is rapidly taken up into cellular DNA, it is easy to discriminate
fluorescent nuclei with no detectable cytoplasmic fluorescence. Fluorescence was read
according to the parameters derived from relative spectra: λex 358 nm–λem 461 nm for
DAPI and λex 416 nm–λem 683 nm for P-Pd. DAPI fluorescence from nuclei staining was
used to normalize the fluorescence signal from the plate reader according to the cell number
in each well. Porphyrin uptake was expressed as Intensity of Fluorescence DAPI Related
Index (IFDR).
2.4. Confocal Microscopy
Qualitative uptake of Pd-P in HT-29 and HDF 106-05 cells was performed by confocal
microscopy to investigate its intracellular localization. Specifically, confocal porphyrins
uptake was performed at 24 h after the incubation. A total of 1 × 105 HT-29 and HDF
106-05 cells were seeded in 24-well plate with glass coverslips on the bottom, and 24 h after
the seeding, cells were then incubated with Pd-P (500 µM) for 24 h. Cells on slides were
fixed with 4% PAF (Sigma-Aldrich) for 15 min at room temperature. Cells were washed,
and glass coverslips were placed on slides with Fluoroshield (Sigma-Aldrich) mounting
medium for preserving and preventing rapid photobleaching of the fluorescent probe.
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Confocal images were acquired using a laser scanning (λex 405 nm and λem 633 nm)
confocal microscope (Zeiss LSM5 Pascal, Oberkochen, Germany) with a 40× oil immersion
objective using the multi-track mode. Images were analyzed with ImageJ software (FiJi,
Bristol, UK, version 2.0). In order to quantify the porphyrin fluorescence in HT-29 and HDF
106-05 cells obtained by confocal acquisitions, five cells per each sample in three indepen-
dent regions of the slide were considered, and the following formula for the corrected total
cell fluorescence (CTCF), calculated with Image J, was then used [18]: CTCF = integrated
density − (area of selected cell ×mean fluorescence of background readings).
Data are expressed as CTCF mean of three independent regions.
2.5. GSH Evaluation
The total glutathione level, glutathione disulfide (GSSG) and reduced glutathione
(GSH) of HT-29 and HDF 106-05 as single cell lines was determined using the Glutathione
Assay Kit (Sigma-Aldrich), according to the manufacturer’s instructions. The GSH content
(nmol) was normalized to protein content in each sample by quantifying cell protein
concentration (µg/mL) using the Quant-iT Protein Assay Kit by using the fluorimeter Qubit
(Invitrogen-Life Technologies, Milano, Italy). Calibration was performed by applying a
two-point standard curve, according to the manufacturer’s instructions. Briefly, GSH reacts
with 5,5′-dithiobis (2-nitrobenzoic acid) (DTNB) in a recycling assay and produces GSSG
and the 1,3,5-trinitrobenzene (TNB) anion, which can be detected by absorbance. In turn,
the enzyme glutathione reductase then reduces GSSG, which releases GSH that can react
with another DTNB molecule. Therefore, the rate of TNB production is measured rather
than a single determination of how much DTNB reacts with GSH, as it is proportional to the
initial amount of GSH [8]. The plate was read at 412 nm on a microplate reader Asys UV 340
(Biochrom, Cambridge, UK), and the amount of GSH was expressed in nmol/µg protein.
2.6. Sonodynamic Treatment
HT-29 and HDF 106-05 cells in the exponential growth phase were preincubated in
the dark for 24 h with the sonosensitizer, Pd-P (500 µM), in 6-well plates. For the co-culture
experiments, cells were then washed with PBS, trypsinized with 0.05% trypsin—0.02%
EDTA solution and normalized to 5.0 × 105 cells consisting of an equal amount of HT-29
cells and HDF 106-05 cells (1:1) in 2.5 mL PBS in polystyrene tubes (TPP, Trasadingen,
Switzerland) away from the light. The polystyrene tube (10 mm diameter) containing the
cell suspension was connected to the US transducer by means of a specific mechanical
adaptor, with a chamber filled with temperature controlled ultrapure water, in order to fix
the distance from the transducer at 17 mm, to control the temperature variance and to have
reproducible measurement conditions [19].
US field was generated using a piezoelectric plane wave transducer (25.4 mm diame-
ter), which operates in continuous wave mode at a frequency of 1.866 MHz, connected to
a function generator (Type 33250; Agilent, Santa Clara, CA, USA) and a power amplifier
(Type AR 100A250A; Amplifier Research, Souderton, PA, USA). All the conditions were
then exposed to US generated at a 1.5 W/cm2 intensity for 5 min. An important aspect
to be taken into consideration during US exposure is temperature control to avoid the
hyperthermic effect. Therefore, the temperature of the cell suspension exposed to US was
monitored by a thermocouple sensor (RS Components, Milano, Italy), and the maximum
temperature recorded during the experiments in the US exposed samples was below 29 ◦C.
2.7. Ultrasound Field Characterization
US intensity (I) was measured as I = P/A where P is the US beam power and A is the
cross-sectional area of US beam (A). The standardized method used to measure P is based
on the radiation force balance principle, which is defined as the time averaged force exerted
by an acoustic field on a target that intercepts the US beam. The measuring system was
developed by the National Institute of Metrological Research (INRIM, Torino, Italy) and is
based on a commercial balance (Mettler Toledo, model SAG-285, Columbus, OH, USA).
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Moreover, the spatial distribution of the US pressure has been evaluated by a scanning
tank system (Onda Corp., Sunnyvale, CA, USA) with needle hydrophone (HNA-0400,
Onda Corp.) and a preamplifier (AH-2020, Onda Corp.). During the 5 min insonation
process at our experimental parameters, into the polystyrene tube, a value of maximum
root-mean-square (rms) acoustic pressure of 300 kPa was measured.
2.8. Cytotoxicity Evaluation
At the end of the sonodynamic treatment, 8000 cells were plated in 24-well culture
plates and then manually counted at 24, 48 and 72 h after the treatment, considering five
different regions per well. Cytotoxicity was expressed as percentage (%) according to the
following equation: % cytotoxicity = 100 × (untreated cell number − treated cell number).
2.9. Photodynamic Treatment
HT-29 and HDF 106-05 cells in the exponential growth phase were preincubated in
the dark for 24 h with the sonosensitizer, Pd-P (500 µM), in 6-well plates. For the co-culture
experiments, cells were then washed with PBS, trypsinized with 0.05% trypsin—0.02%
EDTA solution and normalized to 5.0 × 105 cells consisting of an equal amount of colon
cancer cells and fibroblast cells (1:1) in 2.5 mL PBS in polystyrene tubes (TPP) protected
from the light. The light-emitting source of the system is based on InGaN light-emitting
diodes (Cree Inc, Durham, NC, USA) with 20 mW maximum radiant power (emitted
flux), and a central wavelength of 405 nm. The system allows continuous radiant flux
regulation from 0 to 20 mW, with a programmable non-switching diode current source and
energy fluency rates were adjusted to 15 mW/cm2. In particular, cell suspensions were
illuminated for 5 min in a dark box. Following the photodynamic treatment, 8000 cells
were plated in 24-well culture plates, and then manually counted at 24, 48 and 72 h after
the treatment, considering five different regions per well. Cytotoxicity was expressed as
a percentage according to the following equation: % cytotoxicity = 100 × (untreated cell
number − treated cell number).
2.10. Flow Cytometry Assay
Cytofluorimetric assays were performed using a C6 flow cytometer (Accuri Cytome-
ters, Annarbor, MI, USA) in order to investigate intracellular ROS production and mito-
chondrial membrane potential.
2.10.1. Intracellular ROS Production
Intracellular ROS generation after sonodynamic and photodynamic treatment in
HT-29 or HDF 106-05 cells was investigated by using the 2,7-dichlorodihydrofluorescein
diacetate (DCFH-DA; Sigma-Aldrich) probe. Briefly, cells in the exponential growth phase
were incubated with Pd-P 500 µM for 24 h, and 10 µM DCFH-DA for the last 30 min of
incubation at 37 ◦C protected from light. Cells were then washed with PBS, trypsinized
and exposed to sonodynamic and photodynamic treatment as previously described. ROS
production was assessed at 1, 5, 15, 30 and 60 min after treatments, and 10,000 events were
considered for analysis by the FL1 channel (λex 532 nm). ROS production was expressed as
the integrated mean fluorescence intensity (iMFI), which was calculated as the product of
the mean fluorescence intensity of the cells and the frequency of ROS-producing cells. The
iMFI ratio was then calculated in order to yield the ratiometric increase in fluorescence per
time point related to the iMFI of untreated cells, i.e., control cells [20].
2.10.2. Mitochondrial Membrane Potential
The effects that sonodynamic treatment had on HT-29 or HDF 106-05 cell mitochon-
drial membrane potential was investigated using the Membrane Potential Detection Kit
(BD Bioscience, San Jose, CA, USA) by flow cytometry. Mitochondrial functionality is
related to optimal vital cellular status. Changes in mitochondrial membrane potential,
particularly depolarization, were reported to occur during many cellular processes, such
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as production of ROS, activation of apoptosis and necrosis. 5,5′,6,6′-tetrachloro-1,1′,3,3′-
tetraethylbenzimidazolcarbocyanine iodide (JC-1) is a membrane-permeable lipophilic
cationic fluorochrome that penetrates cells, and its fluorescence is a reflection of mitochon-
drial membrane potential (∆ψ). The fluorescence emission spectrum of JC-1 is dependent
on the status of ∆ψ. JC-1 excites at λex 488–490 nm and can exist in two different states, ag-
gregates (λem 590 nm) or monomers (λem 527 nm), each with a different emission spectrum;
both states exhibit fluorescence by FL-1 channel (λem 532 nm, green) but aggregates are
also detectable by the FL-2 channel (λem 585 nm, red). When live cells are incubated with
JC-1, the JC-1 penetrates the plasma membrane and mitochondria membrane. In polarized
membranes of functional mitochondria conditions JC-1, accumulates in aggregate form,
conversely, in depolarized membranes of less functional mitochondria JC-1 leaks out of the
mitochondria and accumulates into the cytoplasm in monomeric form.
Briefly, HT-29 or HDF 106-05 cells were incubated for 24 h with P-Pd 500 µM at
37 ◦C and then exposed to US, as previously described. Moreover, a positive control was
performed by exposing cells to 500 µM H2O2 for 3 h. JC-1 aggregates and monomers were
investigated for each condition, and 10,000 events were recorded by the FL1 channel (λem
532 nm) and the FL2 channel (λem 585 nm); compensation was required due to fluorophore
monomers and aggregates with partially overlapping emission spectra. Regions were
placed around HT-29 or HDF 106-05 cell populations with high JC-1 aggregates and high
monomer concentration (functional mitochondria); other regions were placed around
HT-29 or HDF 106-05 cell populations with low JC-1 aggregates and high JC-1 monomer
concentration (less functional mitochondria). For quantitative analysis, ∆ψ was expressed
as the ratio between JC-1 aggregate and monomer mean fluorescence emission.
2.11. Membrane Fluidity/Phospholipid Polarization
The influence that US exposure had on HT-29 or HDF 106-05 cell membrane fluid-
ity/phospholipid polarization was investigated by 1,6-diphenyl-1,3,5-hexatriene (DPH)
fluorescence anisotropy using a polarized fluorescence spectrometer (LS 55 PerkinElmer,
USA). DPH powder (MW = 232.32 g/mol) was dissolved to a final concentration of 2 mM
in tetrahydrofuran (Sigma-Aldrich). Then, the pH of DPH final working solution (final
concentration of 2 µM DPH in PBS) used for cells was measured and a value of pH 7.00
was obtained. HT-29 or HDF 106-05 cells were unexposed or exposed to US, as previously
described. Positive controls for the reduction in anisotropy (increase in membrane fluidity
and polarization) were obtained by exposing cells at 45 ◦C for 30 min [21,22]. Immedi-
ately after treatments, cells were incubated with working solution (2 µM DPH) at room
temperature and protected by light. DPH anisotropy was evaluated at 30 and 90 min
after being treated five times. Data are expressed as mean values ± standard deviation.
The excitation wavelength and the detection wavelength were set at λex 365 nm and λem
420 nm, respectively, and the excitation and emission split widths were set at 5 nm and





where I is the fluorescence emission intensity and subscript V and H represent the vertical
and horizontal excitation and emission polarized light orientations. G is a grating factor
that accounts for differences in sensitivity to horizontal and vertical polarized light and is
calculated as G = IHV/IHH [23]. In particular, membrane fluidity/phospholipid polarization
was expressed as DPH fluorescence anisotropy.
2.12. Statistical Analysis
Data are shown as mean values ± standard deviation of three independent experi-
ments. Statistical analyses were performed using Prism 7.0 software (GraphPad, La Jolla,
CA, USA). According to the design of the experiment under analysis, multiple t-tests, two-
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way ANOVA, one-way ANOVA and Bonferroni’s test were used to calculate the threshold
of significance. The statistical significance threshold was set at p < 0.05.
3. Results
3.1. Pd-P Uptake in HT-29 and HDF 106-05 Cells
In order to evaluate the best suitable time to perform sonodynamic and photody-
namic treatment, HT-29 and HDF 105-06 cells were incubated with 500 µM Pd-P complex,
and the relative intracellular fluorescence intensity was evaluated as IFDR. As shown in
Figure 1, in HT-29 and HDF 106-05 cells, the porphyrin uptake increased over time, up to
a maximum level at 24 h and, in the HDF 106-05 cells, porphyrin uptake was statistically
significantly higher compared to HT-29 over time, up to 12 h. Moreover, at 24 h, the
porphyrin uptake was not significantly different between the two cell lines. Therefore, for
subsequent sonodynamic and photodynamic experiments, 24 h was selected as the suitable
time for the Pd-P incubation, representing the best level of sensitizer uptake for both HT-29
and HDF 105-06 cells.
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Figure 1. Pd-P cellular uptake in HT-29 and HDF 105-06 cells over time. HT-29 and HDF 105-06 cells
were incubated for 1, 6, 12 and 24 h with 500 µM Pd-P, and stained with DAPI. Sample fluorescence
intensity was determined using a fluorescent plate reader and expressed as intensity of fluorescence
DAPI related (IFDR). Statistically significant difference versus HT-29 cells: * p < 0.05, ** p < 0.01.
Furthermore, to establish the cellular localization of the metal-porphyrin complex,
a confocal fluorescence analysis of 500 µM P-Pd in HT-29 and HDF 106-05 cells was
performed after 24 h of incubation. As shown in Figure 2a, Pd-P principally showed a
cytoplasmic distribution. In particular, in HDF 106-05 cells, more flu rescent aggregates
were visible at the cytoplasmic level and throughout the cellular body, whereas in HT-29
cells, more fluorescent aggregates were visible in the perinuclear regions. Finally, from
confocal fluorescence analysis, we were also able to confirm that the concentration of the
Pd-P complex in both cell lines, after 24 h incubation of the Pd-P complex, was statistically
significantly different compared to the basal autofluorescence of untreated cells by CTCF
quantification (Figure 2b).
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exposed only to US. Indeed, no statistically significant cytotoxicity was observed on HDF 
106-05 cells in the co-culture model. These data demonstrated that even if cancer cells and 
normal cells were treated simultaneously in a co-culture, they preserved a different re-
sponsiveness over time to the sonodynamic treatment, similar to that observed when they 
were treated as separate cell lines [12]. 
Since oxidative stress is the main mechanism responsible for SDT-induced cytotoxi-
city, to gain further insight on the reason why HT-29 and HDF 106-05 cell lines showed a 
different response to SDT (Figure 3), the basal level of reduced glutathione—the major 
intracellular antioxidant system—was investigated in each cell line. 
Figure 2. Pd-P cellular localization and quantification in HT-29 and HDF 105-06 cells after 24 h incubation. (a) Representative
confocal fluorescence images of HT-29 and HDF 106-05 cells at 40×magnification (scale bar 25 µm): untreated HT-29 cells
(bright fluorescence), HT-29 cells incubated for 24 h with 500 µM of Pd-P (red fluorescence), untreated HFD 106-05 cells
(bright fluorescence) and HFD 106-05 cells incubated for 24 h with 500 µM of Pd-P (red fluorescence). (b) The confocal
fluorescence quantification at 24 h is expressed as corrected total cell fluorescence (CTCF). Statistically significant difference
versus untreated cells: * p < 0.05, ** p < 0.01. Statistically significant difference of HDF 106-05 cells incubated with Pd-P
versus HT-29 cells incubated with Pd-P: ◦ p < 0.05.
3.2. Effect of Sonodynamic and Photodynamic Treatment on Co-Cultured HT-29 and HDF Cells
Considering our previous results on the different responsiveness of cancer HT-29 and
normal HDF 106-05 c lls when eparately subjected to son dynamic treatment [12], we
decided to investigate the Pd-P activation by US on a co-culture model between these two
cell lines. Observing Figure 3, a significant increase in cytotoxicity was observed only on
HT-29 cells when the cells in co-culture were incubated with 500 µM Pd-P and exposed
to US (p < 0.01), compared to untreated co-culture, co-culture treated with the Pd-P alone
or exposed only to US. Indeed, no statistically significant cytotoxicity was observed on
HDF 106-05 cells in the co-culture model. These data demonstrated that even if cancer cells
an normal cells were treated simultaneously in a co-culture, they preserved a differe t
respon iveness ver time to the sonodynamic treatment, similar to that observed wh n
they were treated as separate cell lines [12].
Since oxidative stress is the main mechanism responsible for SDT-induced cytotoxicity,
to gain further insight on the reason why HT-29 and HDF 106-05 cell lines showed a
different response to SDT (Figure 3), the basal level of reduced glutathione—the major
intracellular antioxidant system—was investigated in each cell line.
As shown in Figure 4, no statistically significant difference in intracellular GSH levels
was observed between HT-29 (0.63 ± 0.04) and HDF 106-05 (0.81 ± 0.08) cells, suggesting a
similar ole of the glu athione system in defense against oxidative str ss in both cell lines.
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Figure 4. Intracellular GSH levels according to cell type. The total glutathione level of HT-29 and
HDF 106-05 cells at a basal level, i.e., unt eated cells, was analyz d using the Glutathione Assay
Kit (Sigma-Aldrich) according to the manufacturer’s in tructions nd the GSH content (nmol) was
normalized to the protei content (µg) of the sample.
Of note, when the HT-29 and HDF 106-05 co-culture underwent photodynamic treat-
ment at the appropriate light wavelength, we observed significant cytotoxicity in both cell
lines in co-culture compared to untreated co-culture, co-culture treated with Pd-P alone
and exposed only to the light (Figure 5).
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3.3. Effect of Sonodynamic and Photodynamic Treatment on ROS Production
Since it has been shown that not only photodynamic but also sonodynamic-mediated
porphyrin activatio leads to significant intracellular ROS producti n [24–27], the ROS
generation in HT-29 and HDF 106-05 was evaluated after sonodynamic or photodynamic
treatment compared to untreated cells and cells exposed only to US or light by using
the DCFH-DA cytofluorimetric assay. In HT-29 cells, a significant increase in ROS was
observed after 5 (p < 0.05), 15 (p < 0.01) and 30 (p < 0.001) min from the SDT, with a slight
decline at 60 min (p < 0.01) compared to untreated cells (Figure 6a). A small but statistically
significant increase in ROS production was observed after 5 (p < 0.05), 15 (p < 0.05) and
30 (p < 0.05) min from the US exposure alone compared to untreated cells; this ROS
eneration was not able to induce cell damage as shown in Figure 3. In HDF 106-05 cells,
no ROS production was observed over time after each single treatment, and even after SDT
(Figure 6b), demonstrating an important difference in ROS production between cancer cells
and normal cells, mirroring the cytotoxicity data (Figure 3).
Conversely, after PDT, the maximum in ROS production was observed at 30 min in HT-
29 cells (Figure 6c, p < 0.001) and at 60 min in HDF-106 cells (Figure 6d, p < 0.001). The PDT-
mediated ROS production is therefore in line with the PDT cytotoxicity observed in both
cell lines (Figure 5). These results lead to the suggestion that the main difference between
SDT and PDT in HT-29 and HDF-106 cytotoxicity and ROS generation could be ascribed to
specific cell structures, such as plasma membrane and mitochondria, due to the different
physical nature of the waves employed, electromagnetic and mechanical, respectively.
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3.4. Effects of US Exposure on Cytoplasmic Cell Membrane Fluidity 
Considering the different behavior of cancer HT-29 and normal HDF 106-05 cells ex-
posed to SDT in co-culture, and the possible role played by differences in their cytoplas-
mic cell membrane in eliciting, under US exposure, the intramembrane cavitation accord-
ing to the BLS theory [16], the plasma membrane fluidity of each cell line before and after 
US exposure was investigated. This study was carried out to support our hypothesis that, 
in the presence of differences in mechanical properties of the plasma membrane, a differ-
ent development of intramembrane cavitation can take place. Accordingly, the resulting 
modification in the US-induced energy transfer across the plasma cell membrane can lead 
to differences in the sonosensitizer activation. 
Cell membrane fluidity was investigated by evaluating the fluorescence anisotropy 
of 1,6-diphenyl-1,3,5 hexatriene (DPH), a lipid probe which stains the hydrophobic core 
of the cell membrane. Briefly, when a significant decrease in DPH fluorescence anisotropy 
is measured, a substantial increase in membrane fluidity occurs, indicating that cell mem-
Figure 6. Reactive oxygen species production after sonodynamic or photodynamic treatment. HT-29 (a,c) and HDF 106-05
(b,d) cells were incubated for 24 h with 500 µM Pd-P and then exposed to US (1.5 W/cm2 at 1.866 MHz, for 5 min) or to
light (15 mW/cm2 at 405 nm, for 5 min) at the appropriate wavelength (405 nm). ROS levels were determined at different
time points after each treatment (1, 5, 15, 30 and 60 min) with 2′, 7′-dichlorofluorescein diacetate (DCF-DA) assay using flow
cytometry. Results are expressed as the integrated mean fluorescence (iMFI) ratio. Statistically significant difference versus
untreated cells: * p < 0.05, ** p < 0.01, *** p < 0.001.
3.4. Effects of US Exposure on Cytoplasmic Cell Membrane Fluidity
Considering the different behavior of cancer HT-29 and normal HDF 106-05 cells ex-
posed to SDT in co-culture, and the possible role played by differences in their cytoplasmic
cell membrane in eli iting, under US exposure, the i tramembrane cavitation according
to the BLS theory [16], the plasma membrane fluidity of each cell line before and after US
exposure was investigated. This study was carried out to support our hypothesis that, in
the presence of differences in mechanical properties of the plasma membrane, a different
development of intramembrane cavitation can take place. Accordingly, the resulting modi-
fication in the US-induced energy transfer across the plasma cell membrane can lead to
ifferences in the sonosensitizer activation.
Cell membrane fluidity was investigated by evaluating the fluorescence anisotropy of
1,6-diphenyl-1,3,5 hexatriene (DPH), a lipid probe which stains the hydrophobic core of
the cell membrane. Briefly, when a significant decrease in DPH fluorescence anisotropy is
measured, a substantial increase in membrane fluidity occurs, indicating that cell membrane
lipid chains are more lax. Figure 7 shows a statistical difference in fluorescence anisotropy
between the two cell lines, with a higher DPH fluorescence anisotropy in HDF 106-05
compared to HT-29 cells at basal/control conditions, i.e., when cells are untreated (p < 0.001).
This means that the two cell lines have different starting cell membrane conditions, with
the cell membrane of cancer cells being ore fluid compared to th one of normal cells.
The bserved stro g modification (p < 0.001) in the membrane fluidity of HT-29 under US
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exposure, compared to that observed in HDF-106 cells, suggests a significant change in
the HT-29 cytoplasmic cell membrane, which could support a different intramembrane
cavitation development under US exposure of the two cell lines.
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3.5. Effects of Sonodynamic Treatment on Mitochondrial Function 
The different behavior between HT-29 and HDF 106-06 cells in co-culture under SDT 
may be caused by dissimilarity in the US-induced energy transfer across their plasma 
membrane resulting from the observed different plasma membrane fluidity. This phe-
nomenon could also influence the sonosensitizer activation and, accordingly, mitochon-
dria, which play a central role for a variety of cellular processes such as intracellular ROS 
generation and Ca2+ signaling [28] and are a key element for the US-mediated sonosensi-
tizer activation and the SDT efficacy [29]. To this end, the mitochondrial functionality as 
mitochondrial membrane potential was investigated in both cell lines immediately after 
the sonodynamic treatment. The cytofluorimetric JC-1 assay on HT-29 cells showed an 
increase in fluorescent monomeric forms and a subsequent significant reduction in the 
aggregates-to-monomers ratio, due to a mitochondrial membrane potential reduction 
when cells underwent sonodynamic treatment (Figure 8, 35.8 ± 3.2% p < 0.001). However, 
when HDF 106-05 cells were exposed to the same sonodynamic treatment, no difference 
in the JC-1 aggregates/monomers was observed (Figure 8, 86.3 ± 9.2%), highlighting a mi-
tochondrial function similar to that of untreated cells. Therefore, this result supports our 
hypothesis that a connection is present between plasma membrane fluidity and US-in-
duced energy transfer across the plasma membrane. In other words, differences between 
cell lines in plasma membrane fluidity could be responsible for differences in cellular re-
sponses to SDT, such as intracellular sonosensitizer activation, ROS production, mito-
chondrial membrane potential reduction and cell death. 
Figure 7. Effects of US exposure on cell membrane fluidity. HT-29 and HDF 106-05 cells were
unexposed or exposed to US (1.5 W/cm2 at 1.866 MHz, for 5 min). Membrane fluidity/polarization
was evaluated at different time points after the treatment (30 and 90 min) by the DPH (1,6-diphenyl-
1,3,5-hexatriene) fluorescence anisotropy assay using a polarized spectrophotometer. Membrane
fluidity/polarization was expressed as DPH fluorescence anisotropy. Statistically significant differ-
ence of untreated HDF 106-05 versus untreated HT-29 cells: $$$ p < 0.001. Statistically significant
differenc versus untreated cells: *** p < 0.001.
3.5. Effects of Sonodynamic Treatment on Mitochondrial Function
The different behavior between HT-29 and HDF 106-06 cells in co-culture under SDT
may be caused by dissimilarity in the US-induced energy transfer across their plasma mem-
bran resulting from the bserved different plasma membrane fluidity. This phenomenon
could also influence the sonosensitizer activation and, accordingly, mitochondria, which
play a central role for a variety of cellular processes such as intracellular ROS generation
and Ca2+ signaling [28] and are a key element for the US-mediated sonosensitizer activation
and the SDT efficacy [29]. To this end, the mitochondrial functionality as mitochondrial
membrane potential was investigated in both cell lines immediately after the sonody-
namic treatment. The cytofluorimetric JC-1 assay on HT-29 cells showed an increase in
fluorescent mo omeric forms and a subsequent significant reducti n in the aggregates-
to-monomers ratio, due to a mitochondrial membrane potential reduction when cells
underwent sonodynamic treatment (Figure 8, 35.8 ± 3.2% p < 0.001). However, when HDF
106-05 cells were exposed to the same sonodynamic treatment, no difference in the JC-1
aggregates/monomers was observed (Figure 8, 86.3 ± 9.2%), highlighting a mitochondrial
function similar to that of untreated cells. Therefore, this result supports our hypothesis
that a con ection is present between plasma membrane fluidity and US-induced energy
transfer across the plasma membrane. In other words, differences between cell lines in
plasma membrane fluidity could be responsible for differences in cellular responses to SDT,
such as intracellular sonosensitizer activation, ROS production, mitochondrial membrane
potential reduction and cell death.
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Figure 8. Cell mitochondrial membrane potential after sonodynamic treatment. HT-29 and HDF 
106-05 cells were incubated for 24 h with 500 μM Pd-P and then exposed to US (1.5 W/cm2 at 1.866 
MHz, for 5 min). Mitochondrial membrane potential was evaluated by JC-1 assay immediately after 
treatment by flow cytometry and expressed as percentage of JC-1 aggregates to monomers fluores-
cence ratio in each sample. A positive control was obtained by exposing cells to H2O2 (500 μM) for 
3 h. The mitochondrial membrane potential of untreated cells is represented by the dashed line. 
Statistically significant difference versus untreated cells: *** p < 0.001. 
4. Discussion 
One of the main goals of anticancer drug therapy is to determine the selective de-
struction of cancer cells while leaving normal cells unaffected. Indeed, the poor drug se-
lectivity towards cancer cells is one of the main causes of severe side effects associated 
with cytotoxic chemotherapeutic drugs [30]. Developing targeted therapies such as small 
molecule inhibitors and antibody targeted therapies has significantly improved the spec-
ificity of cancer treatment [31], but improvement can also be achieved by studying US-
based treatment that takes advantages of structural differences between cancer cells and 
normal cells [14]. To this end, the use of US to activate intracellular sonosensitizer, in the 
so-called sonodynamic treatment, could be very promising. Sonodynamic treatment 
works with low intensity US, which avoids temperature increases in the target site, to 
trigger the cytotoxic nature of sensitizers such as porphyrins [32]. Porphyrins are well-
known photosensitizers as their tetrapyrrole ring structure can be activated by light to 
generate ROS, causing damage to cell structures and cell death [33]. These features also 
make porphyrins also suitable sonosensitizers, i.e., compounds responsive to US, due to 
the hypothesis of the sonoluminescence occurrence under appropriate US exposure [34]. 
In order to investigate if the sonodynamic treatment could be a selective cancer treat-
ment, a co-culture of human colon cancer HT-29 and fibroblast HDF 106-05 cells was de-
veloped. The palladium (II) porphyrin complex (Pd-P) was chosen as the sonosensitizer 
as it is well-accepted that the anticancer efficacy of sonodynamic treatment relies on the 
induction of a strong ROS generation due to the US-mediated activation of the sonosensi-
tizer. Indeed, we previously showed that the insertion of Pd (II) in the porphyrin rings 
results in highly efficient ROS production under US exposure [12]. 
Before investigating the possible differences in response to the SDT by the two cell 
lines considered in co-culture, i.e., HT-29 and HDF 106-05, Pd-P uptake by the two cell 
lines was investigated in order to establish the optimal incubation time to perform SDT. 
Therefore, HT-29 and HDF 106-05 cells were incubated with the same noncytotoxic Pd-P 
concentration at different time points, and intracellular fluorescence quantification was 
performed, showing similar Pd-P uptake after 24 h of incubation in both cell lines (Figure 
1). Interestingly, focusing on confocal images (Figure 2), it was possible to note a prefer-
ential Pd-P localization in the perinuclear regions of HT-29 cell cytoplasm, while Pd-P was 
localized all over the cellular body in the HDF 106-05 cell cytoplasm. Since it has been 
reported that in cancer cells, mitochondria are mostly localized at a perinuclear level, 
whereas in normal cells, they are spread all over the cellular body [35,36], and it has been 
Figure 8. Cell mitochondrial membrane potential after sonodynamic treatment. HT-29 and HDF
106-05 cells were incubated for 24 h with 500 µM Pd-P and then exposed to US (1.5 W/cm2 at
1.866 MHz, for 5 min). Mitochondrial membrane potential was evaluated by JC-1 assay immediately
after treatment by flow cytometry and expressed as percentage of JC-1 aggregates to monomers
fluorescence ratio in each sample. A positive control was obtained by exposing cells to H2O2 (500 µM)
for 3 h. The mitochondrial membrane potential of untreated cells is represented by the dashed line.
Statistically significant difference versus untreated cells: *** p < 0.001.
4. Discussion
One of the main goals of anticancer drug therapy is to determine the selective de-
struction of cancer cells while leaving normal cells unaffected. Indeed, the poor drug
selectivity towards cancer cells is one of the main causes of severe side effects associated
with c totoxic chemotherapeutic drugs [30]. Developing target d therapies su h as small
molecule inhibitors and antibody ta geted therapies has significantly improved the speci-
ficity of ca cer treatment [31], but improv ment c n al o be achieved by studying US-based
treatment that tak s advantages of structural differences betwe n cancer cells and normal
cells [14]. To this end, the use of US to activate intracellular sonosensitizer, in the so-called
sonodynamic treatment, could be very promising. Sonodynamic treatment works with low
intensity US, which avoids temperature increases in the target site, to trigger the cytotoxic
nature of sensitizers such as porphyrins [32]. Porphyrins are well-known photosensitizers
as their tetrapyrrole ring structure can be activated by light to generate ROS, causing
damage to cell structures and cell death [33]. These features also make porphyrins also
suitable sonosensitizers, i.e., compounds responsive to US, due to the hypothesis of the
sonoluminescence occurrence under appropriate US exposure [34].
In order to investigate if the sonodynamic treatment could be a selective cancer treat-
ment, a co-culture of human colon cancer HT-29 and fibroblast HDF 106-05 cells was
developed. The palladium (II) porphyrin co plex (Pd-P) was chosen as the sonosensitizer
as it is well-accepted that the anticancer efficacy of sonodynamic treatment reli s on the
induction of a strong ROS gene ation due to the US-mediated activation of the s nosen-
itizer. Indeed, we previously showed that the insertion f Pd (II) in the porphyrin rings
results i highly efficient ROS production under US exposure [12].
Before investigating the possible differences in response to the SDT by the two cell
lines considered in co-culture, i.e., HT-29 and HDF 106-05, Pd-P uptake by the two cell
lines was investigated in order to establish the optimal incubation time to perform SDT.
Therefore, HT-29 and HDF 106-05 cells were incubated with the same noncytotoxic Pd-P
concentration at different time points, and intracellular fluorescence quantification was
performed, showing similar Pd-P uptake after 24 h of incubation in both cell lines (Figure 1).
Interestingly, focusing on confocal images (Figure 2), it was possible to note a preferential
Pd-P localization in the perinuclear regions of HT-29 cell cytoplasm, while Pd-P was
localized all over the cellular body in the HDF 106-05 cell cytoplasm. Since it has been
reported that in cancer cells, mitochondria are mostly localized at a perinuclear level,
whereas in normal cells, they are spread all over the cellular body [35,36], and it has been
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considered that porphyrins accumulate preferentially in mitochondria [37], we suggested
that the Pd-P complex preferentially accumulated in the mitochondria in both cell lines.
Following the results of the Pd-P uptake experiments in our cell lines, SDT was
carried out in a co-culture of HT-29 and HDF 106-05 cells (1:1), showing a very significant
cytotoxicity over time on HT-29 cells, but not on HDF 106-05 cells (Figure 3). To avoid
any misinterpretations in our cytotoxic results between HT-29 and HDF 106-05 cells in
co-culture, due to a possible difference in responses to the oxidative stress trigger by SDT,
the amount of intracellular GSH was investigated. Indeed, cells can have a common
antioxidant defensive strategy against ROS action, and one of the most important is the
GSH redox cycle, able to metabolize hydrogen peroxide and to minimize its participation
in reactions leading to hydroxyl radical formation [38,39]. In HT-29 and HDF 106-05 cell
lines, no statistically significant difference in the intracellular amount of GSH was observed,
suggesting that the response of the GSH system to oxidative stress could be similar in
both the considered cell lines (Figure 4) and, most importantly, that our different cytotoxic
results between HT-29 and HDF 106-05 cells in our co-culture model did not appear to be
affected by the amount of intracellular GSH.
To understand the different cytotoxicity observed between HT-29 and HDF 106-05
cells in co-culture after the sonodynamic treatment, we investigated the cytotoxic effect of a
photodynamic treatment with the same sensitizer, Pd-P, on the same HT-29 and HDF 106-05
co-culture. Indeed, SDT was developed as a novel, promising non-invasive anticancer
approach derived from PDT and, furthermore, it is well known that the low selectivity of
PDT towards malignant cells is mainly due to the direct transmission of light energy to the
sensitizer without involving structures or intracellular organelles that could be different
among cells, such as the outer cell membrane [40]. Therefore, after 24 h of incubation of a
noncytotoxic concentration of Pd-P in both cell lines, our HT-29 and HDF 106-05 co-culture
was subjected to PDT, and a significant cytotoxicity over time in both cancer HT-29 and
normal HDF 106-05 cell lines was observed (Figure 5). To confirm these findings, the ROS
production in our co-culture was investigated both after STD and PDT, since oxidative
stress is the main mechanism underlying the cytotoxic effect of both treatments. ROS were
strongly generated in HT-29 cells, but not in HDF 106-05 cells when our co-culture was
subjected to sonodynamic treatment, whereas a strong ROS generation in both cell lines was
observed when our co-culture was subjected to PDT (Figure 6), mirroring the cytotoxicity
data. These data are in line with other reports confirming the strong ROS production as the
pivotal step in the sonodynamic and photodynamic cytotoxic effect [8,41].
Since the major difference between SDT and PDT is the energy source used to acti-
vate the sensitizer (US versus light), this discrepancy between the SDT and PDT results
suggested that US and light could activate the intracellular sensitizer differently in HT-29
and HDF 106-05 cells, probably due to the diverse nature of the wave, mechanical and elec-
tromagnetic, and therefore a different mechanism and amount of energy deposited to the
sensitizer. Specifically, our findings suggested that, in SDT, the US-mediated intracellular
sensitizer activation could be more influenced by differences in the cell structure of HT-29
and HDF 106-05 cells compared to PDT because, due to the type of energy released from
the light, the selectivity of photodynamic action can be better achieved investigating cell
organelles-targeted photosensitizers instead of cell structure differences between normal
and cancer cells [42].
In order to understand whether the cell structure plays a role in the selective cyto-
toxicity towards cancer cells during SDT, plasma membrane fluidity and mitochondrial
membrane potential in both cell lines were investigated. Our choice to initially focus
our attention on the plasma cell membrane was based on strong evidence that malignant
and normal cells differ not only in their metabolism and morphology, but also in the
plasma cell membrane architecture. This latter aspect can lead to differences in terms of
mechanical properties between cancer cells and normal cells, being crucial for the success
of the sonodynamic approach, as the sonosensitizer intracellular activation is mediated
by an US-induced energy transfer across the plasma cell membrane [43–45]. Indeed, one
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of the main interesting hypotheses explaining the US-induced energy transfer across the
cell membrane to activate the intracellular sonosensitizer is represented by the bilayer
sonophore (BLS) theory. According to this theory, Krasovitski et al. suggested that the
cytoplasmic membrane, under appropriate conditions, is capable of transforming the US
oscillating acoustic pressure wave into an intramembrane cavitation, which could explain
all US-induced bioeffects [16]. In other words, this cyclic expansion and contraction of
the BLS could stimulate cycles of stretch and release in the plasma membrane and in the
cytoskeleton, becoming a source of intramembrane cavitation. Therefore, we suggest that
this kind of cavitation could generate intracellular submicron-sized gas bubbles that, when
collapsed, release very high energy and perhaps also sonoluminescence [34].
Therefore, our hypothesis was that the SDT selective cytotoxicity between HT-29
and HDF 106-05 cells could be based on BLS occurrence, thanks to our US set-up and
according to the different mechanical properties of the plasma membrane of the two cell
lines considered. Therefore, to investigate our hypothesis, we studied an important plasma
membrane feature that could affect, according to BLS hypothesis, the US-induced energy
transfer across the plasma membrane namely, the cell membrane fluidity. Cell membrane
fluidity was analyzed by using DPH, a lipid probe that is able to link phospholipid chains
contained in the cytoplasmic membrane bilayer, where an increase in DPH fluorescence
anisotropy occurs in the presence of destabilized phospholipid polarization, being related
to increased cell membrane fluidity [22,46]. Specifically, HDF 106-05 normal cells at basal
conditions, i.e., without US exposure, showed a significantly lower membrane fluidity
compared to HT-29 cancer cells, with normal cells being stiffer than cancer cells (Figure 7).
These data are in agreement with other studies that reported cancer cells as being more
compliant to physical stimuli such as acoustic waves than normal cells, and this evidence could
support the preferential response of cancer cells to sonodynamic treatment [14,47]. Indeed,
some researchers demonstrated that normal cells and cancer cells display differences in
cell–cell interactions, cytoskeleton organization and subcellular structure, determining a
specific elasticity and, therefore, distinct mechanical phenotypes [44,45,47]. Indeed, cancer
cells, in general, appear softer than their normal counterparts, while conversely, normal
cells show greater stiffness and higher resistance to mechanical stress compared to cancer
cells [13,14,43]. Therefore, the observed difference in cell membrane fluidity between the
two cell lines under investigation could be related to the selective response of cancer cells
to the sonodynamic treatment. The difference highlighted between cancer cells and normal
cells in their responsiveness to sonodynamic treatment is also supported by Kosheleva’s
work, where it was noticed that the synergistic cytotoxic effects of US and nanoparticles
were more pronounced in A549 lung cancer cells than in their normal counterparts, BEAS-
2B cells [48]. Moreover, after US exposure, we observed a decrease in membrane fluidity
for HT-29 (Figure 7), suggesting a bilayer cell membrane separation, as described in Di
Giacinto’s work [49]. Therefore, our results could support the hypothesis that SDT cytotoxic
selectivity between HT-29 and HDF 106-05 cells may be based on the BLS theory thanks to
our US set-up, and according to a different mechanical property of the plasma membrane
between the two cell lines.
Another important aspect that can elucidate and highlight the differences between
cancer cells and normal cells under SDT is related to the effect of SDT on HT-29 and HDF
106-05 mitochondria, since mitochondria are one of the main ROS mediators, playing
a pivotal role in controlling process that can lead to cell death [50]. Furthermore, mi-
tochondria are an important subcellular target for sensitizers, and are also sensitive to
US exposure [27,51–53]. Therefore, mitochondrial membrane potential was investigated,
and a significant mitochondrial membrane potential reduction, along with a subsequent
mitochondria dysfunction, was only observed when cancer HT-29 cells underwent son-
odynamic treatment (Figure 8). These data are in line with the sonodynamic-induced
cytotoxicity in HT-29 cells and the inefficacy of this treatment in inducing cytotoxicity in
HDF 106-05 cells. Therefore, the different SDT responses between the two cell lines in
our co-culture model could be also ascribed to a different effect on mitochondria, in line
Cancers 2021, 13, 3852 16 of 18
with diverse sensitizer activation under US exposure, occurring in cancer cells and not in
normal cells, in accord with the BLS theory.
5. Conclusions
Cancer cells and normal cells are considerably different in cell structure and mechani-
cal properties. Our data highlight a marked difference between cancer cells and normal cells
in term of responsiveness to the sonodynamic treatment, with US being able to selectively
trigger the cytotoxicity of the intracellular sonosensitizer on cancer cells only. This different
behavior between cancer cells and normal cells that is responsible for different US-induced
bioeffects can be ascribed to diversity in plasma membrane properties such as membrane
fluidity according to the BLS theory. The observed significant lower stiffness of cancer cells
compared to normal cells could allow an efficient US energy transfer to the intracellular
sonosensitizer in mitochondria in cancer cells only, overcoming one of the main drawbacks
in cancer therapy, namely the selectivity. Therefore, plasma membrane properties could
influence the sonodynamic treatment despite what has been observed in photodynamic
treatment, increasing the interest in exploiting SDT as a significant advancement in the
battle against cancer.
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